TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2028626
Drug: Actisomide 8.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actisomide 8.4 mg/kg
Study: 2028626
Drug: Actisomide 2.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actisomide 2.1 mg/kg
Study: 27471050
Drug: Comprehensive care
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive care programme (IG) including education from a respiratory nurse, physiotherapist support for pulmonary rehabilitation, 3-monthly telephone calls by a respiratory nurse for 1 year, and follow-up at a respiratory clinic with a respiratory specialist once every 3 months for 1 year.
Study: 9780750
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional fluid therapy)
Study: 8166152
Drug: NPN (neomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPN (neomycin 250 mg QID, polymyxin‐B 100 mg QID, nalidixic acid 1,000 mg BID)
Study: 26376650
Drug: Oral perhexiline
Normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral perhexiline for a median of 9 days
Study: 23159133
Drug: Colloid solution
Normalized name: colloidal oatmeal Topical Solution
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colloid solution
Study: 15170391
Drug: Crystalloid solution
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid solution
Study: 18046927
Drug: Inhaled dry
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dry powder insulin (IDPI)
Study: 7914104
Drug: 2-chlorodeoxyadenosine (2-CdA)
Normalized name: 2-Chlorodeoxyadenosine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-chlorodeoxyadenosine (2-CdA) administered as a single 120-hour continuous infusion (8.9 mg/m2 of body surface area per day)
Study: 3342158
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no thrombolytic treatment)
Study: 30589098
Drug: Benidipine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine (8 mg)
Study: 27240265
Drug: Befriending (supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befriending (supportive treatment)
Study: 25365653
Drug: Topiramate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (300 mg)
Study: 24182325
Drug: Cetrorelix (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (5 mg/day on days 1 and 2; 3 mg/day on days 3-5)
Study: 7993833
Drug: Preoperative combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative combined chemotherapy (TMF regimen: thiotepa 20 mg, methotrexate 40 mg/m2, 5-fluorouracil 500 mg/m2) plus radiotherapy (Group I)
Study: 7993833
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy only (Group II)
Study: 7993833
Drug: Preoperative combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative combined chemotherapy plus radiotherapy (Group I)
Study: 3140327
Drug: Metaproterenol solution
Normalized name: metaproterenol Inhalation Solution
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol solution
Study: 3140327
Drug: Cromolyn solution
Normalized name: cromolyn Oral Solution
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn solution
Study: 26223254
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (6 mm) alone
Study: 26223254
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (8 mm) combined with osteotome sinus floor elevation (OSFE)
Study: 26223254
Drug: Standard implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard implants (10 mm) combined with osteotome sinus floor elevation (OSFE)
Study: 20554506
Drug: Selective retina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective retina therapy (SRT) using Q-switched Nd:YLF laser, wavelength 527 nm, t=1.7 μs, energy 100-370 μJ, spot diameter 200 μm, pulse repetition rate 100 Hz
Study: 18929279
Drug: Cisatracurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.1 mg/kg (Group A)
Study: 18929279
Drug: Cisatracurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.15 mg/kg (Group B)
Study: 18929279
Drug: Cisatracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.2 mg/kg (Group C)
Study: 14652364
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg elemental iron with 1 mg riboflavin
Study: 14652364
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg elemental zinc with 1 mg riboflavin
Study: 14652364
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg iron and 20 mg zinc with 1 mg riboflavin
Study: 14652364
Drug: Micronutrient mix
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient mix (MM) containing 20 mg iron, 20 mg zinc, 1 mg riboflavin along with other minerals and vitamins
Study: 14652364
Drug: Control treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment, 1 mg riboflavin only
Study: 1452950
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement containing protein (20.4 g), mineral salts (Ca: 0.525 g), and vitamins A = 750 IU; D3 = 25 IU, 250 ml/day for a mean of 38 days
Study: 1452950
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received the same supplement dose but with no protein, 250 ml/day for a mean of 38 days
Study: 6362490
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of epinephrine
Study: 6362490
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of phenylephrine
Study: 6362490
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of phenylephrine
Study: 6362490
Drug: Epinephrine and
Normalized name: Epinephrine and zinc only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine and phenylephrine (at equipotent doses)
Study: 30275690
Drug: GLY 25
Normalized name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 25 g in 100 g TOPICAL STICK [Pit Boss Antiperspirant and Deodorant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLY 25 µg twice daily
Study: 30275690
Drug: GLY 50
Normalized name: Gly
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLY 50 µg twice daily
Study: 30275690
Drug: TIO 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO 18 µg once daily
Study: 24266596
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of 1000 units of human pasteurized C1‐INH concentrate
Study: 24266596
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of 1000 units of human pasteurized C1‐INH concentrate
Study: 18310627
Drug: Synera patch
Normalized name: lidocaine / tetracaine Medicated Patch [Synera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synera patch and saline infiltration
Study: 18310627
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch and 2% lidocaine infiltration
Study: 15808659
Drug: Thymoglobulin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (1.5 mg/kg per dose during the anhepatic period and two doses every other day)
Study: 9015776
Drug: Allergen specific
Normalized name: Allergen specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen specific immunotherapy (IT)
Study: 9015776
Drug: Allergen specific
Normalized name: Allergen specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen specific immunotherapy (IT) with grass pollen extracts
Study: 25491541
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acupoints BL23 and KI3
Study: 20016147
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of stabilized rice bran once daily for 12 weeks
Study: 11075561
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hANP infusion)
Study: 1315827
Drug: Low-sodium, low-fat/high-fibre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium, low-fat/high-fibre diet (less than 60 mmol sodium/day; 30% fat energy; P:S ratio = 1; 30-50 g fibre/day)
Study: 1315827
Drug: Low-sodium, normal-fat/normal-fibre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium, normal-fat/normal-fibre diet (less than 60 mmol sodium/day; 40% fat energy; P:S ratio = 0.3; 15 g fibre/day)
Study: 3889076
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg/d for days 1-6, 360 mg/d for days 7-12)
Study: 3889076
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg/d for days 1-6, 480 mg/d for days 7-12)
Study: 3889076
Drug: Verapamil (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (combined with quinidine 750 mg/d for part III)
Study: 3889076
Drug: Quinidine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (750 mg/d for part III)
Study: 31041591
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available meal replacement product (2 servings/day) + other supplements
Study: 29662303
Drug: Sterimar Mn
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterimar Mn nasal spray (4 puffs/day) for 5 months
Study: 26372606
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g sucrose in 500 mL water
Study: 26372606
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g sucrose in 500 mL water
Study: 26372606
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g sucrose (control)
Study: 22307942
Drug: OCR 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCR 200 mg + MTX
Study: 22307942
Drug: OCR 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCR 500 mg + MTX
Study: 17438216
Drug: Rotigotine 8
Normalized name: ROTIGOTINE 8MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 8 mg/24 hours
Study: 17438216
Drug: Rotigotine 12
Normalized name: Rotigotine 125 microgram/hour prolonged-release transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 12 mg/24 hours
Study: 12183307
Drug: Handrubbing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handrubbing with alcohol based solution (n=12)
Study: 1969402
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg twice daily (A)
Study: 1969402
Drug: Nadolol 40
Normalized name: nadolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 40 mg twice daily (N)
Study: 31169651
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral subcostal TAP block with 20 ml of levobupivacaine 0.375% and epinephrine 5 μg/ml
Study: 31169651
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline with epinephrine 5 μg/ml (Control)
Study: 27233381
Drug: Higher urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher urine potassium excretion (measured as 1-SD increase in baseline urine potassium level)
Study: 26410153
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine with 1:100,000 epinephrine plus buccal and lingual infiltration and preoperative oral ketorolac
Study: 26410153
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine with 1:100,000 epinephrine plus buccal and lingual infiltration
Study: 26410153
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:80,000 epinephrine plus buccal and lingual infiltration
Study: 23482074
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) turned on
Study: 23482074
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) turned off
Study: 21677021
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (PRT) targeting lower limb muscles, twice a week for 10 weeks
Study: 17091411
Drug: Group intervention
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group intervention program consisting of education, ergonomics, exercises, pain management, advice for daily life movement, pelvic belt/crutches, and information about delivery (n=275)
Study: 17091411
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no treatment (n=285)
Study: 29991131
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (singing group)
Study: 19043908
Drug: Integrated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated group program involving social group work intervention and Chinese medicine therapeutics
Study: 16390558
Drug: Pure crystalloid
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure crystalloid priming solution
Study: 10780867
Drug: Alendronate 2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 2.5, 5, or 10 mg/day for 1 year
Study: 8721381
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interferon‐gamma (100 micrograms) administered subcutaneously daily for 10 days (first trial)
Study: 8721381
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interferon‐gamma (100 micrograms) administered subcutaneously daily for 21 days (second trial)
Study: 6689277
Drug: Mepindolol alone
Normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepindolol alone (10 mg)
Study: 6689277
Drug: Mepindolol and
Normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepindolol and Hydrochlorothiazide in combination (Tenesor)
Study: 30028922
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment protocol (control group)
Study: 26589633
Drug: 4-monthly BoNT-A
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-monthly BoNT-A injections
Study: 26589633
Drug: 12-monthly BoNT-A
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-monthly BoNT-A injections
Study: 12575969
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy with EDTA
Study: 10588313
Drug: Grepafloxacin 400
Normalized name: grepafloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grepafloxacin 400 mg od for 5 days
Study: 10588313
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg bd for 10 days
Study: 1929681
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy with bleeding episode
Study: 23212802
Drug: Cystatin C
Normalized name: Cystatin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystatin C > 2.04 mg/L
Study: 23212802
Drug: ESAM >
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESAM > 34 ng/mL
Study: 16216315
Drug: MVAC (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVAC (methotrexate 30 mg/m2 days 1, 15, and 22; vinblastine 3 mg/m2 days 2, 15, and 22; doxorubicin 30 mg/m2 day 2; cisplatin 70 mg/m2 day 2 q 4 weeks)
Study: 16216315
Drug: TC (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC (cisplatin 50 mg/m2 day 1 and topotecan 0.75 mg/m2 days 1‐3 q 3 weeks)
Study: 16216315
Drug: C (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (cisplatin 50 mg/m2 q 3 weeks)
Study: 12663724
Drug: Once-daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral etoposide (50 mg/m2/d)
Study: 12663724
Drug: Twice-daily oral
Normalized name: Ferriprox 1000 MG Twice-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily oral etoposide (50 mg/m2/d)
Study: 12663724
Drug: Once-daily vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily vs twice-daily oral etoposide
Study: 11382798
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein intake of 0.8 g protein.kg(‐1).day(‐1) for 14 weeks
Study: 3538363
Drug: pindolol 10
Normalized name: pindolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol 10 mg once daily for 4 weeks
Study: 3538363
Drug: atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 100 mg once daily for 4 weeks
Study: 31280619
Drug: masitinib 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: masitinib 4.5 mg/kg/d
Study: 31280619
Drug: masitinib 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: masitinib 3.0 mg/kg/d
Study: 21504954
Drug: Home-based physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physiotherapy (twice weekly for eight weeks)
Study: 18004495
Drug: Nursing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing intervention with telephone checkups twice a week
Study: 12639491
Drug: MF59-adjuvanted H5N3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine
Study: 12639491
Drug: Non-adjuvanted H5N3
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted H5N3 A/Duck/Singapore/97 vaccine
Study: 10957701
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and codeine suppository (60 mg codeine and 800 mg paracetamol) with standard premedication of intramuscular midazolam 0.08 mg/kg
Study: 10957701
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository and midazolam
Study: 1534961
Drug: Paroxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (30 mg/day) for 6 weeks
Study: 1534961
Drug: Amitriptyline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (150 mg/day) for 6 weeks
Study: 16327580
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) at a low dose of 0.5 mg/kg divided in two equal doses
Study: 10802793
Drug: Zolmitriptan 5
Normalized name: zolmitriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 5 mg and 10 mg
Study: 8627080
Drug: Stavudine (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine (0.1, 0.5, 1.0, or 2.0 mg/kg/day)
Study: 1600040
Drug: Combined omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined omeprazole (40 mg mane) and ranitidine (50 mg bolus followed by 12.5 mg/h)
Study: 1600040
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg mane)
Study: 1600040
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg bolus followed by 12.5 mg/h)
Study: 31759891
Drug: Elagolix (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix (oral, nonpeptide gonadotropin-releasing hormone antagonist)
Study: 21343146
Drug: Ad5-vectored HIV-1
Normalized name: Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-vectored HIV-1 vaccine
Study: 21343146
Drug: Ad5-vectored HIV-1
Normalized name: Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-vectored HIV-1 vaccine (in subset with protective HLA types B27, B57, B58)
Study: 18222010
Drug: Concomitant carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concomitant carboplatin and radiotherapy (50mg/m² IV infusion twice weekly, 54-72Gy, 30-40 fractions, 6-8 weeks)
Study: 10733441
Drug: Epoprostenol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol plus conventional therapy
Study: 8939323
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin B12 injections
Study: 2856949
Drug: Tamoxifen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (30 mg daily for one year)
Study: 27083430
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy (nucleotide/nucleoside analogues)
Study: 26181088
Drug: Norethindrone acetate
Normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethindrone acetate (5 mg/day) plus conjugated equine estrogens (0.625 mg/day)
Study: 16841623
Drug: Bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion XL (300-450 mg/day)
Study: 30644312
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg seltorexant
Study: 30644312
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg seltorexant
Study: 30644312
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg seltorexant
Study: 28183335
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (50,000 IU weekly for 3 weeks, then 2000 IU daily until 1 year post ART initiation)